Puma Biotechnology (PBYI) 33.41 $PBYI Biotechnology

New Post Public Reply Private Reply Replies (0) Message Board

Jun 13, 2016 at 2:19 AM

Puma Biotechnology (PBYI) 33.41 $PBYI

Biotechnology Equities Technical Notes -- Grifols, Achillion Pharma, Jazz Pharma, and Puma Biotechnology
PR Newswire - Wed Jun 08, 7:25AM CDT
On Tuesday, June 07, 2016, the NASDAQ Composite ended the trading session at 4,961.75, down 0.14%; the Dow Jones Industrial Average advanced 0.10% to finish at 17,938.28; and the S&P 500 closed at 2,112.13, up 0.13%. The gains were broad based as eight out of nine sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Grifols S.A. (NASDAQ: GRFS), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), and Puma Biotechnology Inc. (NYSE: PBYI). Learn more about these stocks by accessing their free trade alerts at:
ACHN: 9.55 (-0.18), JAZZ: 150.76 (-5.26), GRFS: 16.96 (-0.23), PBYI: 33.41 (-0.43)

Puma (PBYI) Presents Favorable Phase II Data on Neratinib
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 8:33AM CDT
Puma Biotechnology (PBYI) presented positive data from a phase II study on neratinib in patients with HER2-mutated, non-amplified breast cancer at ASCO.
ANIP: 52.05 (-1.64), AZN: 27.97 (-0.99), RTRX: 17.40 (-0.30), PBYI: 33.41 (-0.43)

Puma Biotechnology Presents Positive Phase II Data at the 2016 ASCO Annual Meeting
BusinessWire - Sun Jun 05, 8:05AM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, presented positive results from an investigator-sponsored Phase II trial of neratinib with HER2-mutated, non-amplified breast cancer. The data were presented today in a poster discussion session at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting in Chicago, Illinois. The poster (Abstract #516), entitled "Phase II Trial of Neratinib for HER2 Mutated, Non-Amplified Metastatic Breast Cancer (HER2mutMBC)," was presented from 8:00-11:30 a.m. CDT today with a poster presentation discussion occurring immediately following the poster session.
PBYI: 33.41 (-0.43)

Sunesis Pharmaceuticals Appoints Linda Neuman, M.D., as Vice President, Clinical Development
GlobeNewswire - Wed Jun 01, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that Linda Neuman, M.D., has been appointed to the role of Vice President, Clinical Development. Dr. Neuman brings 10 years of clinical practice and 13 years of industry experience to Sunesis, most recently serving as Senior Medical Director of Oncology at Puma Biotechnology.
SNSS: 0.54 (-0.01), PBYI: 33.41 (-0.43)

Puma Biotechnology Announces Publication of Neratinib Abstract for the 2016 ASCO Annual Meeting
BusinessWire - Wed May 18, 4:05PM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced the release of an abstract on its drug candidate PB272 (neratinib) that will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 3-7, 2016, in Chicago. Abstracts are available to the public online on the ASCO website: www.abstract.asco.org.
PBYI: 33.41 (-0.43)

Puma (PBYI) Reports Wider Loss in Q1, Neratinib in Focus
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:06AM CDT
Puma Biotechnology (PBYI) reported a wider-than-expected loss of $2.19 per share in the first quarter of 2016.
ANIP: 52.05 (-1.64), RTRX: 17.40 (-0.30), BMY: 72.65 (-0.08), PBYI: 33.41 (-0.43)

Puma Biotech reports 1Q loss
Automated Insights - Tue May 10, 5:06PM CDT
LOS ANGELES (AP) _ Puma Biotechnology Inc. (PBYI) on Tuesday reported a loss of $71 million in its first quarter.
PBYI: 33.41 (-0.43)

Puma Biotechnology Reports First Quarter 2016 Financial Results
BusinessWire - Tue May 10, 3:17PM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2016.
PBYI: 33.41 (-0.43)

Drug Stocks Reporting Early Next Week: TEVA, ARNA & More
Arpita Dutt - Zacks Investment Research - Fri May 06, 8:43AM CDT
Drug companies like Teva (TEVA) and Arena (ARNA) will be reporting results early next week.
BDSI: 2.67 (-0.18), INO: 10.62 (-0.39), VVUS: 1.19 (-0.03), TEVA: 53.01 (-0.30), ARNA: 1.99 (-0.07), PBYI: 33.41 (-0.43)

What Awaits Puma Biotechnology (PBYI) in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Wed May 04, 2:58PM CDT
Puma Biotechnology (PBYI) is expected to report first-quarter 2016 results on May 9.
IPXL: 32.45 (-1.11), JAZZ: 150.76 (-5.26), PBYI: 33.41 (-0.43)

Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference
BusinessWire - Wed May 04, 7:35AM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 10:40 a.m. PDT on Wednesday, May 11, at the Bank of America Merrill Lynch 2016 Health Care Conference. The conference will be held at Encore at the Wynn in Las Vegas.
PBYI: 33.41 (-0.43)

Puma Biotechnology's NEfERT-T Phase II Study Published Online in JAMA Oncology
BusinessWire - Thu Apr 14, 10:10AM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that results from the NEfERT-T Phase II clinical trial of neratinib in ERBB2-positive metastatic breast cancer patients were published online in JAMA Oncology. The article, entitled "Neratinib Plus Paclitaxel vs. Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial," appears in the April 14, 2016 online issue and will be published in a future print issue of the journal.
PBYI: 33.41 (-0.43)

Why Puma Biotechnology, Inc. Stock Crashed 37% in March
Cory Renauer, The Motley Fool - Motley Fool - Mon Apr 11, 8:21AM CDT
Image source: Puma Biotechnology. What: Shares of Puma Biotechnology , a biopharmaceutical company dedicated to development of novel cancer therapies, fell 36.6% last month, according to data from S&P Global Market Intelligence . ...
PBYI: 33.41 (-0.43)

Why is Puma Biotech Stock (PBYI) Plummeting Today?
Andrew Steele - Zacks Investment Research - Tue Mar 29, 12:04PM CDT
Puma Biotechnology is having a terrible day of trading. Why is that?
PBYI: 33.41 (-0.43)

Puma's (PBYI) Filing for Breast Cancer Drug Neratinib Delayed
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 10:20AM CDT
Puma Biotechnology (PBYI) announced that the regulatory filing for its breast cancer drug neratinib will be delayed until mid-2016.
AMAG: 21.04 (-0.82), ANIK: 49.16 (+0.24), PBYI: 33.41 (-0.43)

Puma Biotechnology Updates Timeline for Filing New Drug Application
BusinessWire - Mon Mar 28, 3:10PM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that based on its recent meetings with the U.S. Food and Drug Administration (FDA), the Company now plans to submit its New Drug Application (NDA) for the approval of neratinib for the treatment of extended adjuvant breast cancer that has previously been treated with a trastuzumab-containing regimen in mid-2016.
PBYI: 33.41 (-0.43)

Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2016
BusinessWire - Fri Mar 18, 7:30AM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced publication of abstracts on neratinib for the American Association for Cancer Research (AACR) Annual Meeting 2016. The AACR Annual Meeting will be held at the Ernest N. Morial Convention Center in New Orleans from April 16 to April 20.
PBYI: 33.41 (-0.43)

Endometrial Cancer Pipeline Market Research H2 2015 Report
PR Newswire - Wed Mar 02, 8:00PM CST
A market research report titled "Endometrial Cancer - Pipeline Review, H2 2015" provides an overview of the Endometrial Cancer's therapeutic pipeline and enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
INCY: 80.41 (-1.20), IMGN: 4.96 (-0.11), ARQL: 1.78 (unch), LLY: 73.95 (-0.48), GSK: 40.93 (-1.13), ONTY: 1.21 (+0.02), MDVN: 60.01 (-0.09), MRK: 56.81 (-0.37), AZN: 27.97 (-0.99), AVEO: 1.03 (-0.03), GALE: 2.08 (+0.10), PBYI: 33.41 (-0.43), NVS: 78.94 (-1.57), KPTI: 8.53 (-0.60), XLRN: 35.44 (+0.94), EXEL: 7.38 (+0.01)

Puma Biotechnology to Present at Cowen's Health Care Conference
BusinessWire - Wed Mar 02, 3:15PM CST
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 11:20 a.m. EST on Wednesday, March 9, at the Cowen and Company 36th Annual Health Care Conference. The conference will be held at the Boston Marriott Copley Place.
PBYI: 33.41 (-0.43)

First Week of April 15th Options Trading For Puma Biotechnology (PBYI)
DividendChannel.com - Wed Mar 02, 9:37AM CST
Investors in Puma Biotechnology, Inc. saw new options become available this week, for the April 15th expiration.
PBYI: 33.41 (-0.43)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

TIOmarkets App Unveils Enhanced Trading Features

Trading on the Go Takes a Leap Forward Pretty slick development from TIOmarkets, if I do say so myself. They've rolled out a major expansion of their mobile trading app, now packing some hefty features like Depth of Market and more granular order controls right from those little devices in our pockets. Quite the leap if you're one of those folks who can't keep your eyes...

DAR Logs Massive 587,000 Service Hours Nationwide

A Month of Patriotism and Service You've got to hand it to the Daughters of the American Revolution (DAR)—when they commit, they go all in. This year, they turned their usual Day of Service into a full-blown Month of Service, packing in over 587,000 hours of volunteering nationwide. From historic spots to food pantries, DAR members showed up, and honestly, it's the kind...

Bechtel's $1M Push for Wyoming's Skilled Trades Future

Wyoming's Bid for Skilled Trades Revolution You’d think with all the talk about tech and white-collar jobs, we’ve forgotten the backbone that keeps the world ticking—skilled trades. Turns out, Bechtel hasn’t. The company just tossed a cool million at Wyoming's Laramie County Community College and Western Wyoming College. What’s that doing? It's jumpstarting...

Ashling's New Feat: Microsoft Recognition in AI

Microsoft's Stamp of Approval for Ashling Ah, recognition—it's not just for egos. When Ashling, an AI consultancy heavyweight, gets a nod from Microsoft, it's worth more than a footnote in the company newsletter. This isn't some participation trophy. Nope, it's a badge saying they know their Data & AI, and Digital & App Innovation inside out. On October 29, 2026,...

Newmark's Q3 2026 Financials: Revenue Surges to $3.7B

Breaking Down Newmark's Latest Numbers Ah, Newmark—stepping up again with their quarterly results, and boy, it was nothing short of a spectacle. They just rolled out their third-quarter financials for 2026, and numbers don't lie; they're strutting with $3.7 billion in revenue over the past twelve months. Now, if that doesn't make the investors grin from ear to ear, I...

Pencil Reinvention Aims to Reduce Classroom Waste

Sharpen Those Ideas: Reinventing the Humble Pencil Every classroom has 'em: pencils chewed up faster than a kid chomping through bubblegum. This ain't new. But dig this—a Chicago teacher's coming in hot with a tweak to extend pencil life. How? By addressing the ol' crumbly eraser issue. You know, the kind that vanishes into thin air right when you need it most. So,...

Meitu Sees Soaring Subscriber Growth Amid AI Focus

Subscriber Growth Hits a Record High Well, here's a headline to chew on—Meitu, Inc. is boasting a whopping 19.83 million paying subscribers, setting a new milestone. That's 1.39 million new users this quarter alone, the most significant uptick they've seen in four cycles. Not that I'm surprised; when you've got a product mix like theirs that's riding high on the wave of...

Bandwidth Welcomes Chip Schroeder: Key Board Makeover

Turning the Page at Bandwidth Bandwidth Inc. (NASDAQ:BAND) just shook up its executive roster by bringing in a heavy hitter. Chip Schroeder's landing on the board is a bold move from a strategic player in the cloud communications space. This guy's not your average board member; he's a veteran navigator through stormy market waters, and at Bandwidth, it seems he'll be...

Markel's Reinsurance Shift with $4.8B Deal: Strategic Move?

Weaving Through Complex Insurance Terrain When Markel Insurance pulls a move on the chessboard that involves $4.8 billion in subject reserves, we better pay attention. The insurance bigwig has inked a reinsurance deal with Enstar. This plan, they say, will help them focus more on their specialty insurance game while tidying up the loose ends in their global reinsurance...

Wabi's $1.25B Valuation: A New Era for AI?

A Major Milestone for Wabi Well, here we go—Wabi, the brainchild of Eugenia Kuyda, is stirring the pot with a massive $55 million funding round, pulling its valuation up to a hefty $1.25 billion. If you're raising eyebrows at that price tag, you’re not alone. It's a big number riding on an even bigger idea: that AI isn't just for solitary chats anymore, but for...